FNDC10

Summary

FNDC10 (fibronectin type III domain containing 10, HGNC:42951) is a protein-coding gene on chromosome 1p36.33, encoding Fibronectin type III domain-containing protein 10 (F2Z333).

Predicted to be located in membrane.

Source: NCBI Gene 643988 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 2 total — 1 pathogenic
• Phenotypes (HPO): 1
• MANE Select transcript: NM_001242659

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:42951
Approved symbol	FNDC10
Name	fibronectin type III domain containing 10
Location	1p36.33
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000228594
Ensembl biotype	protein_coding
Entrez	643988

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000422725

RefSeq mRNA: 1 — MANE Select: NM_001242659 NM_001242659

CCDS: CCDS55559

Canonical transcript exons

ENST00000422725 — 1 exons

Exon	Start	End
ENSE00001792737	1598012	1600135

Expression profiles

Bgee: expression breadth ubiquitous, 191 present calls, max score 89.91.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 2.8952 / max 40.9479, expressed in 1131 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
9807	2.1223	973
9806	0.5972	303
9805	0.1757	97

Top tissues by expression

242 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
pancreatic ductal cell	CL:0002079	89.91	silver quality
right adrenal gland cortex	UBERON:0035827	87.55	gold quality
right adrenal gland	UBERON:0001233	87.16	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	86.74	gold quality
left adrenal gland cortex	UBERON:0035825	86.69	gold quality
left adrenal gland	UBERON:0001234	86.26	gold quality
hypothalamus	UBERON:0001898	86.01	gold quality
adrenal cortex	UBERON:0001235	85.75	gold quality
right frontal lobe	UBERON:0002810	85.74	gold quality
anterior cingulate cortex	UBERON:0009835	85.30	gold quality
Brodmann (1909) area 9	UBERON:0013540	83.64	gold quality
adrenal gland	UBERON:0002369	83.31	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	83.04	gold quality
amygdala	UBERON:0001876	82.36	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	81.85	gold quality
apex of heart	UBERON:0002098	81.09	gold quality
tibialis anterior	UBERON:0001385	80.93	silver quality
stromal cell of endometrium	CL:0002255	80.32	gold quality
ileal mucosa	UBERON:0000331	80.15	gold quality
neocortex	UBERON:0001950	80.15	gold quality
cerebral cortex	UBERON:0000956	79.98	gold quality
Ammon’s horn	UBERON:0001954	79.60	gold quality
frontal cortex	UBERON:0001870	79.37	gold quality
primary visual cortex	UBERON:0002436	79.34	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	79.32	gold quality
nucleus accumbens	UBERON:0001882	79.26	gold quality
substantia nigra	UBERON:0002038	79.11	gold quality
forebrain	UBERON:0001890	78.95	gold quality
temporal lobe	UBERON:0001871	78.70	gold quality
kidney epithelium	UBERON:0004819	78.61	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.44

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

45 targeting FNDC10, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3134	100.00	66.43	777
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-1184	99.99	68.19	1458
HSA-MIR-4715-3P	99.98	66.03	670
HSA-MIR-8082	99.95	67.27	1170
HSA-MIR-4731-5P	99.89	67.23	2537
HSA-MIR-124-3P	99.89	73.74	3043
HSA-MIR-506-3P	99.89	73.55	3057
HSA-MIR-10395-5P	99.86	67.35	676
HSA-MIR-6875-3P	99.82	70.26	2983
HSA-MIR-518A-5P	99.70	69.01	2209
HSA-MIR-527	99.70	69.01	2209
HSA-MIR-10394-5P	99.65	66.83	1852
HSA-MIR-1205	99.65	66.76	1826
HSA-MIR-4251	99.40	69.19	3363
HSA-MIR-4685-5P	99.25	65.99	1563
HSA-MIR-6837-5P	99.25	65.47	1632
HSA-MIR-4784	99.15	67.41	1733
HSA-MIR-6768-3P	99.14	67.38	1319
HSA-MIR-4651	99.06	67.57	2002
HSA-MIR-3619-5P	99.00	68.87	2308
HSA-MIR-608	98.93	67.83	2013
HSA-MIR-3150B-3P	98.81	67.21	1728
HSA-MIR-760	98.81	66.65	1392
HSA-MIR-331-3P	98.76	64.91	793
HSA-MIR-6761-5P	98.71	68.03	1504
HSA-MIR-214-3P	98.71	68.12	2128
HSA-MIR-6804-5P	98.39	65.77	1084
HSA-MIR-4704-3P	98.28	69.33	1300
HSA-MIR-4664-5P	98.17	65.07	1020

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	fndc10	ENSDARG00000078657
mus_musculus	Fndc10	ENSMUSG00000074738
rattus_norvegicus	Rps15al2	ENSRNOG00000030447

Protein

Protein identifiers

Fibronectin type III domain-containing protein 10 — F2Z333 (reviewed: F2Z333)

All UniProt accessions (1): F2Z333

UniProt curated annotations — full annotation on UniProt →

Subcellular location. Membrane.

RefSeq proteins (1): NP_001229588* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR034446	Fndc10	Family

Pfam: PF17742

UniProt features (8 total): topological domain 2, glycosylation site 2, signal peptide 1, chain 1, transmembrane region 1, domain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-F2Z333-F1	77.51	0.38

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Glycosylation sites (2): 86, 109

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 36 (showing top): GSE45365_CTRL_VS_MCMV_INFECTION_NK_CELL_UP, chr1p36, GSE13522_CTRL_VS_T_CRUZI_Y_STRAIN_INF_SKIN_IFNAR_KO_UP, ZNF563_TARGET_GENES, MIR608, MIR4651, MIR4534, MIR3192_5P, MIR8082, MANNO_MIDBRAIN_NEUROTYPES_HSERT, HARALAMBIEVA_PBMC_M_M_R_II_AGE_11_22YO_VACCINATED_VS_UNVACCINATED_7YR_DN, HE_LIM_SUN_FETAL_LUNG_C1_SMG_CELL, GSE24142_ADULT_VS_FETAL_DN2_THYMOCYTE_UP, WP_1P36_COPY_NUMBER_VARIATION_SYNDROME, PULVER_FOREY_CELLCYCLE_PEAKING_EG1

GO Biological Process (0):

GO Molecular Function (0):

GO Cellular Component (1): membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	1

Protein interactions and networks

STRING

416 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
FNDC10	FNDC7	Q5VTL7	616
FNDC10	FANK1	Q8TC84	456
FNDC10	LRFN5	Q96NI6	428
FNDC10	CRTAC1	Q9NQ79	419
FNDC10	FLRT1	Q9NZU1	404
FNDC10	IGFN1	Q86VF2	401
FNDC10	FLRT2	O43155	333
FNDC10	FNDC9	Q8TBE3	324
FNDC10	FNDC1	Q4ZHG4	321
FNDC10	TARM1	B6A8C7	317
FNDC10	ANKFN1	Q8N957	279
FNDC10	SLPI	P03973	254
FNDC10	CFAP97	Q9P2B7	247
FNDC10	FNDC5	Q8NAU1	245
FNDC10	SFRP5	Q5T4F7	243

IntAct

2 interactions, top by confidence:

A	B	Type	Score
SLC22A1	FNDC10	psi-mi:“MI:0914”(association)	0.350

BioGRID (3): C1orf233 (Affinity Capture-MS), C1orf233 (Affinity Capture-RNA), C1orf233 (Affinity Capture-MS)

ESM2 similar proteins: A2A9Q0, A5PKD8, A9JSM3, D4A2Q0, E7ERA6, F1SAM7, F2Z333, P0CG25, Q07303, Q0IIA6, Q1RMK9, Q24JP5, Q2MJR0, Q2WF71, Q3MIP1, Q3UV16, Q3ZCQ3, Q504Y2, Q5EBM0, Q5GH56, Q5GH64, Q5GH72, Q5RJI4, Q5SZI1, Q641Q3, Q6IEE6, Q6IQX7, Q6P6N5, Q6UKI2, Q6ZMC9, Q6ZVW7, Q86UD0, Q8IUW3, Q8IZ52, Q8K064, Q8N4K4, Q8NAC3, Q8NBR0, Q8NCL9, Q8NFR9

Diamond homologs: A2A9Q0, D4A2Q0, F2Z333

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

2 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	0
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
523269	GRCh37/hg19 1p36.33-36.31(chr1:834101-6076140)	Pathogenic

SpliceAI

98 predictions. Top by Δscore:

Variant	Effect	Δscore
1:1598396:GGCT:G	acceptor_gain	0.7600
1:1598395:AGGCT:A	acceptor_gain	0.7300
1:1598397:GCT:G	acceptor_gain	0.7200
1:1598398:C:A	acceptor_gain	0.7200
1:1598399:T:A	acceptor_gain	0.6900
1:1599418:C:CT	donor_gain	0.6700
1:1599419:C:CT	donor_gain	0.6300
1:1598394:AAGGC:A	acceptor_gain	0.4800
1:1598406:G:GA	acceptor_gain	0.4700
1:1599449:CGCCG:C	donor_gain	0.4700
1:1599471:T:TA	donor_gain	0.4600
1:1599417:A:AC	donor_gain	0.4200
1:1599160:C:CA	donor_gain	0.4000
1:1599335:T:TA	donor_gain	0.3900
1:1599287:AGGCG:A	donor_gain	0.3800
1:1598380:CCC:C	acceptor_gain	0.3700
1:1598381:CCC:C	acceptor_gain	0.3700
1:1598389:A:C	acceptor_gain	0.3600
1:1598641:AC:A	donor_gain	0.3500
1:1598642:CC:C	donor_gain	0.3500
1:1599274:G:T	donor_gain	0.3500
1:1599400:C:CT	donor_gain	0.3500
1:1599401:C:CT	donor_gain	0.3500
1:1599445:C:T	donor_gain	0.3500
1:1599446:C:T	donor_gain	0.3500
1:1599450:G:T	donor_gain	0.3500
1:1599891:A:AC	donor_gain	0.3500
1:1599292:C:CA	donor_gain	0.3400
1:1599233:T:TG	acceptor_gain	0.3200
1:1598714:CCCT:C	donor_loss	0.3100

AlphaMissense

1415 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:1599412:A:G	C202R	0.999
1:1599426:A:T	M197K	0.999
1:1599498:A:C	F173C	0.999
1:1599660:A:C	F119C	0.999
1:1599680:C:A	W112C	0.999
1:1599680:C:G	W112C	0.999
1:1599737:C:A	W93C	0.999
1:1599737:C:G	W93C	0.999
1:1599852:A:C	F55C	0.999
1:1599426:A:C	M197R	0.998
1:1599498:A:G	F173S	0.998
1:1599627:C:T	C130Y	0.998
1:1599411:C:T	C202Y	0.997
1:1599432:C:T	C195Y	0.997
1:1599433:A:G	C195R	0.997
1:1599435:A:T	I194N	0.997
1:1599497:G:C	F173L	0.997
1:1599497:G:T	F173L	0.997
1:1599499:A:G	F173L	0.997
1:1599621:T:A	D132V	0.997
1:1599699:A:C	F106C	0.997
1:1599410:G:C	C202W	0.996
1:1599423:A:T	L198Q	0.996
1:1599429:A:T	V196D	0.996
1:1599626:G:C	C130W	0.996
1:1599628:A:G	C130R	0.996
1:1599654:C:T	C121Y	0.996
1:1599408:A:G	L203P	0.995
1:1599444:C:T	G191D	0.995
1:1599455:C:A	M187I	0.995

dbSNP variants (sampled 300 via entrez): RS1000869921 (1:1597932 G>C), RS1000895193 (1:1600589 G>A), RS1001276122 (1:1599364 C>G,T), RS1001357756 (1:1601939 T>C), RS1001384644 (1:1598176 C>G), RS1001493233 (1:1599684 G>A,C,T), RS1001881160 (1:1598399 T>A,C), RS1003032696 (1:1601143 G>A), RS1003148933 (1:1601325 T>C,G), RS1003368451 (1:1599332 G>C), RS1003483385 (1:1600393 C>A,T), RS1003902994 (1:1598689 C>T), RS1003956773 (1:1598468 G>A), RS1005056310 (1:1601337 C>T), RS1005380251 (1:1600617 C>A,T)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (1): dilated cardiomyopathy (MONDO:0005021)

Orphanet (1): Dilated cardiomyopathy (Orphanet:217604)

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0001644	Dilated cardiomyopathy

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST005951_34	Body mass index	3.000000e-08

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004340	body mass index

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D002311	Cardiomyopathy, Dilated	C14.280.195.160; C14.280.238.070; C16.320.488.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

22 total (human), top 22 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression	2
Tobacco Smoke Pollution	decreases expression	2
bisphenol A	affects expression	1
2-methyl-4-isothiazolin-3-one	decreases expression	1
ethyl-p-hydroxybenzoate	decreases expression	1
ferrous chloride	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
abrine	decreases expression	1
jinfukang	affects cotreatment, increases expression	1
Air Pollutants	decreases expression, increases abundance	1
Cisplatin	affects cotreatment, increases expression	1
Doxorubicin	decreases expression	1
Lead	affects expression	1
Methotrexate	decreases expression	1
Niclosamide	increases expression	1
Smoke	decreases expression	1
Thimerosal	decreases expression	1
Thiram	decreases expression	1
Valproic Acid	affects expression	1
1-Methyl-4-phenylpyridinium	increases expression	1
Acrylamide	decreases expression	1
Particulate Matter	decreases expression, increases abundance	1

Clinical trials (associated diseases)

158 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00374465	PHASE4	UNKNOWN	Therapy With Verapamil or Carvedilol in Chronic Heart Failure
NCT01293903	PHASE4	COMPLETED	Study of Qiliqiangxin Capsule to Treat Dilated Cardiomyopathy
NCT01557140	PHASE4	COMPLETED	A Randomized Trial of Carvedilol in Chronic Chagas Cardiomyopathy
NCT01917149	PHASE4	COMPLETED	Supramaximal Titrated Inhibition of RAAS in Dilated Cardiomyopathy
NCT02115581	PHASE4	COMPLETED	Coenzyme Q10 Supplementation in Children With Idiopathic Dilated Cardiomyopathy
NCT06236022	PHASE4	RECRUITING	The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus
NCT00333827	PHASE3	COMPLETED	Cell Therapy In Dilated Cardiomyopathy
NCT00505154	PHASE3	COMPLETED	Effect of Rosuvastatin on Left Ventricular Remodeling
NCT01223703	PHASE3	COMPLETED	PUFAs and Left Ventricular Function in Heart Failure
NCT01583114	PHASE3	TERMINATED	PREclinical Mutation CARriers From Families With DIlated Cardiomyopathy and ACE Inhibitors
NCT01914081	PHASE3	UNKNOWN	Resveratrol: A Potential Anti- Remodeling Agent in Heart Failure, From Bench to Bedside
NCT02989181	PHASE3	UNKNOWN	Continues Positive Airway Pressure Treatment for Patients With Dilated Cardiomyopathy and Obstructive Sleep Apnea
NCT03439514	PHASE3	TERMINATED	A Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation
NCT05237323	PHASE3	COMPLETED	Micophenolate Mofetil Versus Azathioprine in Myocarditis
NCT05849766	PHASE3	COMPLETED	Effect of Dapagliflozin on Cardiac Structure, Function and Secondary Mitral Regurgitation in Patients with Left Ventricle Dysfunction
NCT06250257	PHASE3	RECRUITING	Bromocriptine in Dilated Cardiomyopathy Among Women of Reproductive Age
NCT00629018	PHASE2	COMPLETED	Safety and Efficacy Study of Stem Cell Transplantation to Treat Dilated Cardiomyopathy
NCT00629096	PHASE2	COMPLETED	Intracoronary Infusion of Autologous Bone Marrow Cells for Treatment of Idiopathic Dilated Cardiomyopathy
NCT00765518	PHASE2	COMPLETED	Use of Ixmyelocel-T (Formerly Cardiac Repair Cell [CRC] Treatment) in Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM)
NCT00847964	PHASE2	COMPLETED	Safety and Feasibility of Algisyl-LVR™ as a Method of Left Ventricular Restoration in Patients With DCM Undergoing Open-heart Surgery
NCT01020968	PHASE2	COMPLETED	Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated Cardiomyopathy
NCT01302171	PHASE2	COMPLETED	Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy
NCT01350310	PHASE2	COMPLETED	Safety and Efficacy Study of Intramyocardial Stem Cell Therapy in Patients With Dilated Cardiomyopathy
NCT02133911	PHASE2	COMPLETED	A Pilot Trial of Ranolazine to Treat Patients With Dilated Cardiomyopathy
NCT03071653	PHASE2	SUSPENDED	Left Cardiac Sympathetic Denervation for Cardiomyopathy Feasibility Pilot Study
NCT03572660	PHASE2	ACTIVE_NOT_RECRUITING	Use of Bone Marrow Derived Stem Cell and G-CSF With Circulatory Assistance in the Treatment of DCM
NCT03775070	PHASE2	COMPLETED	Simvastatin Therapy in Patients With Dilated Cardiomyopathy.
NCT04405804	PHASE2	UNKNOWN	Early Administration of Ivabradine in Children With Heart Failure
NCT05410873	PHASE2	COMPLETED	Examining the Effects of Mitochondrial Oxidative Stress in DCM
NCT06632834	PHASE2	RECRUITING	Outcome-targeted Therapy: Principle and Outcome Evaluation: Clinical Study and Phenotype-genotype Correlation
NCT00585546	PHASE1	TERMINATED	Harefield Recovery Protocol Study for Patients With Refractory Chronic Heart Failure
NCT02293603	PHASE1	UNKNOWN	Dilated cardiomYopathy iNtervention With Allogeneic MyocardIally-regenerative Cells (DYNAMIC)
NCT03062956	PHASE1	COMPLETED	A Single Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of MYK-491
NCT03129568	PHASE1	COMPLETED	Transcoronary Infusion of Cardiac Progenitor Cells in Pediatric Dilated Cardiomyopathy
NCT04982081	PHASE1	UNKNOWN	Treating Congestive HF With hiPSC-CMs Through Endocardial Injection
NCT06381466	PHASE1	TERMINATED	A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Oral AZD0233 Compared With Placebo in Healthy Adult Participants.
NCT06464588	PHASE1	RECRUITING	A Phase 1 Open-Label Study of the Safety of Intravenous Allogeneic Neonatal Mesenchymal Cells (nMSCs) in Young Adult (1A) and Pediatric (1B) Patients With Dilated Cardiomyopathy (DCM)
NCT06902896	PHASE1	COMPLETED	Safety and Efficacy of FAP iCDC in End-stage Dilated Cardiomyopathy
NCT07137338	PHASE1	RECRUITING	A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated Cardiomyopathy
NCT07241104	PHASE1	RECRUITING	A Study of AZD4063 in PLN R14del Dilated Cardiomyopathy